RxDoctor Payments Data

Kirit Vora, MD

Urology · Sterling Heights, MINPI 1649261108

Payments from drug & device makers

$498in general payments, 2019–2025

Across 29 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$88
  • Astellas Pharma US Inc$85
  • Blue Earth Diagnostics$62
  • Myriad Genetic Laboratories, Inc.$57
  • AbbVie$53
  • Sumitomo Pharma America, Inc.$38
  • plus $115 from 6 others

What the payments were for

  • Food & beverage$498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson5$88
Astellas Pharma US Inc5$85
Blue Earth Diagnostics4$62
Myriad Genetic Laboratories, Inc.3$57
AbbVie(2 entities)3$53
Sumitomo Pharma America, Inc.2$38
Neotract Inc.2$34
Merck1$24
Zyla Life Sciences, Inc.1$19
Halozyme Inc1$13
Coloplast1$13
Rochester Medical Corporation1$11

How this compares

$498 in reported general payments places this provider in the 25th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$195,884
Medicare patients
342
Services billed
4,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ElmironPentosan Polysulfate Sodium16$20,523
GemtesaVibegron12$17,204
Tamsulosin Hcl667$14,383
MyrbetriqMirabegron13$6,673
Oxybutynin Chloride ErOxybutynin Chloride65$2,682
Finasteride139$2,563
Tolterodine Tartrate ErTolterodine Tartrate14$1,769
Solifenacin Succinate25$1,085
Potassium Citrate ErPotassium Citrate11$1,001
Alfuzosin Hcl ErAlfuzosin Hcl19$785
Oxybutynin Chloride16$323
Testosterone Cypionate17$263
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$256
Ciprofloxacin Hcl31$197
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$38$17,20412 claims
Astellas Pharma US IncMyrbetriq$85$6,67313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 400 urology providers in Michigan.

Other urology in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →